Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Arrowhead Pharmaceuticals Inc. shares valued at $237,480 were sold by Oliver Tracie on Jul 02 ’24. At $25.28 per share, Oliver Tracie sold 9,394 shares. The insider’s holdings dropped to 127,107 shares worth approximately $2.44 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Vakiener Victoria sold 1,799 shares, netting a total of over 41,935 in proceeds. Following the sale of shares at $23.31 each, the insider now holds 30,205 shares.
Before that, Hamilton James C had sold 6,000 shares from its account. In a trade valued at $168,180, the Chief Discovery/Trans Medicine traded Arrowhead Pharmaceuticals Inc. shares for $28.03 each. Upon closing the transaction, the insider’s holdings decreased to 6,000 shares, worth approximately $3.94 million.
As published in their initiating research note from Goldman on June 05, 2024, Arrowhead Pharmaceuticals Inc. [ARWR] has been a Neutral and the price target has been revised to $31. Analysts at BofA Securities started covering the stock with ‘”a Buy”‘ outlook in a report released in early December. As of September 19, 2023, Citigroup has initiated its “Neutral” rating for ARWR. Earlier on July 21, 2023, TD Cowen initiated its rating. Their recommendation was “an Outperform” for ARWR stock.
Analyzing ARWR Stock Performance
During the last five days, there has been a drop of approximately -1.03%. Over the course of the year, Arrowhead Pharmaceuticals Inc. shares have dropped approximately -37.19%. Shares of the company reached a 52-week high of $39.83 on 01/10/24 and a 52-week low of $18.15 on 10/01/24. A 50-day SMA is recorded $23.29, while a 200-day SMA reached $26.98. Nevertheless, trading volume fell to 0.76 million shares from 1.47 million shares the previous day.
Support And Resistance Levels for Arrowhead Pharmaceuticals Inc. (ARWR)
According to the 24-hour chart, there is a support level at 18.74, which, if violated, would cause prices to drop to 18.25. In the upper region, resistance lies at 19.57. The next price resistance is at 19.91. RSI (Relative Strength Index) is 33.80 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at -0.84, which suggests the price will decrease in the coming days. Percent R is at 73.12%, indicating bearish price movement. Stochastics %K at holding indicates that the stock is to be held.
